1. Home
  2. CRSP vs SPR Comparison

CRSP vs SPR Comparison

Compare CRSP & SPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CRSP
  • SPR
  • Stock Information
  • Founded
  • CRSP 2013
  • SPR 1927
  • Country
  • CRSP Switzerland
  • SPR United States
  • Employees
  • CRSP N/A
  • SPR N/A
  • Industry
  • CRSP Biotechnology: Biological Products (No Diagnostic Substances)
  • SPR Military/Government/Technical
  • Sector
  • CRSP Health Care
  • SPR Industrials
  • Exchange
  • CRSP Nasdaq
  • SPR Nasdaq
  • Market Cap
  • CRSP 3.4B
  • SPR 3.7B
  • IPO Year
  • CRSP 2016
  • SPR 2006
  • Fundamental
  • Price
  • CRSP $40.53
  • SPR $33.91
  • Analyst Decision
  • CRSP Buy
  • SPR Hold
  • Analyst Count
  • CRSP 19
  • SPR 16
  • Target Price
  • CRSP $77.13
  • SPR $35.67
  • AVG Volume (30 Days)
  • CRSP 1.8M
  • SPR 1.2M
  • Earning Date
  • CRSP 02-19-2025
  • SPR 02-04-2025
  • Dividend Yield
  • CRSP N/A
  • SPR N/A
  • EPS Growth
  • CRSP N/A
  • SPR N/A
  • EPS
  • CRSP N/A
  • SPR N/A
  • Revenue
  • CRSP $202,829,000.00
  • SPR $6,478,200,000.00
  • Revenue This Year
  • CRSP N/A
  • SPR $6.60
  • Revenue Next Year
  • CRSP $724.16
  • SPR $25.00
  • P/E Ratio
  • CRSP N/A
  • SPR N/A
  • Revenue Growth
  • CRSP 19.31
  • SPR 16.62
  • 52 Week Low
  • CRSP $36.52
  • SPR $25.16
  • 52 Week High
  • CRSP $91.10
  • SPR $37.08
  • Technical
  • Relative Strength Index (RSI)
  • CRSP 44.09
  • SPR 57.44
  • Support Level
  • CRSP $36.52
  • SPR $33.61
  • Resistance Level
  • CRSP $40.99
  • SPR $34.44
  • Average True Range (ATR)
  • CRSP 1.78
  • SPR 0.63
  • MACD
  • CRSP 0.23
  • SPR -0.03
  • Stochastic Oscillator
  • CRSP 51.68
  • SPR 65.13

About CRSP CRISPR Therapeutics AG

Crispr Therapeutics is a gene editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for clustered regularly interspaced short palindromic repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. Crispr's first approved drug is Casgevy, which was developed in collaboration with Vertex Pharmaceuticals and targets sickle-cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is advancing a variety of gene editing programs in immuno-oncology, cardiovascular, and a stem cell-derived therapy to treat Type 1 diabetes.

About SPR Spirit Aerosystems Holdings Inc.

Spirit AeroSystems manufactures aerostructures, particularly fuselages, cockpits, wing sections, engine pylons, and nacelles for commercial and military aircraft. The company was spun out of Boeing in 2005, and the firm is the largest independent supplier of aerostructures for commercial aircraft. Boeing and Airbus are the firm's primary customers—Boeing represented roughly 60% and Airbus roughly 20% of revenue in recent years. The company is highly exposed to Boeing's beleaguered 737 program, which accounts for nearly half the company's revenue.

Share on Social Networks: